MediWound (MDWD)
(Delayed Data from NSDQ)
$17.70 USD
+1.35 (8.26%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $17.73 +0.03 (0.17%) 5:28 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
MDWD 17.70 +1.35(8.26%)
Will MDWD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MDWD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MDWD
PTC Therapeutics (PTCT) Reports Q2 Loss, Misses Revenue Estimates
Harrow (HROW) Reports Q2 Loss, Tops Revenue Estimates
MDWD: What are Zacks experts saying now?
Zacks Private Portfolio Services
MediWound (MDWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Strength in Kidney Care Likely to Aid DaVita's (DVA) Q2 Earnings
Product Demand Likely to Aid Organon's (OGN) Q2 Earnings
Other News for MDWD
MediWound’s NexoBrid Triumphs in Burn Care Study
MediWound Announces Positive Results from the U.S. NexoBrid? Expanded Access Protocol (NEXT)
MediWound announces results from NexoBrid Expanded Access Protocol
MediWound to Report Second Quarter 2024 Financial Results
MediWound Announces Publication of the EscharEx? Phase II ChronEx Study Results for Venous Leg Ulcers